DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/mw3ghg/nonalcoholic) has announced the addition of the "Non-Alcoholic Steatohepatitis - Pipeline Review, H2 2015" report to their offering.
This report provides comprehensive information on the therapeutic development for Non-Alcoholic Steatohepatitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Non-Alcoholic Steatohepatitis and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Companies Involved in Therapeutics Development
- AlbireoPharma
- Aquinox Pharmaceuticals Inc.
- Ardelyx, Inc.
- Boehringer Ingelheim GmbH
- Bristol-Myers Squibb Company
- Connexios Life Sciences Pvt. Ltd.
- Daiichi Sankyo Company, Limited
- Dr. Falk Pharma GmbH
- DURECT Corporation
- Dynavax Technologies Corporation
- Enanta Pharmaceuticals, Inc.
- Exicure, Inc.
- Galectin Therapeutics, Inc.
- Galmed International Ltd.
- Genfit SA
- GenKyoTex S.A.
- Gilead Sciences, Inc.
- iCo Therapeutics Inc.
- Merck & Co., Inc.
- Mochida Pharmaceutical Co., Ltd.
- NGM Biopharmaceuticals, Inc.
- Nimbus Therapeutics, LLC
- Nippon Chemiphar Co., Ltd.
- Novartis AG
- Novo Nordisk A/S
- Protalix BioTherapeutics, Inc.
- Regulus Therapeutics Inc.
- RuiYi Inc.
- Shire Plc
- Vascular Biogenics Ltd.
- Verva Pharmaceuticals Limited
- Viking Therapeutics, Inc.
- Virobay Inc.
- Zafgen Inc.
- Zydus Cadila Healthcare Limited
For more information visit http://www.researchandmarkets.com/research/mw3ghg/nonalcoholic
